FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993351741> ?p ?o ?g. }

• W1993351741 endingPage "511" @default.
• W1993351741 startingPage "502" @default.
• W1993351741 abstract "Phosphohistone H3 assessed proliferation has strong prognostic value. Lymph vessel invasion by D2-40 is also prognostic, but D2-40+ myoepithelial expression in small ducts completely filled by solid-pattern ductal carcinoma in situ can mimic lymphovascular invasion. As myoepithelial cells are also p63 positive, we have investigated whether lymph vessel invasion identified by combined D2-40/p63 is stronger prognostically than by D2-40 alone, and whether it has independent prognostic value to phosphohistone H3. In 240 operable T1–2N0M0 node negative invasive breast cancer patients <71 years, phosphohistone H3 was determined by quantitative immunohistochemistry and lymph vessel invasion by D2-40/p63 double immunostaining. Correlation analysis between the clinico-pathologic factors and lymph vessel invasion, and univariate and multivariate prognostic survival analysis were performed. With median 117 (range: 12–192) months follow-up, 36 patients (15%) developed and 28 (12%) died of distant metastases. Ten of the 61 patients (16%) with cancer cells surrounded by D2-40 were p63 positive and none of these ‘false lymph vessel invasion’ recurred. D2-40+/p63− lymph vessel invasion occurred in 51/239 (21%) cases and correlated with grade, mitotic activity index, phosphohistone H3, ER, cytokeratin14, and HER2. D2-40+/p63− lymph vessel invasion was strongly prognostic, but far more in women ≥55 than those <55 years (P<0.0001 and 0.04). With multivariate analysis, phosphohistone H3 proliferation was the strongest single prognosticator. Lymph vessel invasion had additional prognostic value to phosphohistone H3 only in women ≥55. This group of patients, without/with lymph vessel invasion, had 10-year survival rates of 83 and 50%, respectively (hazard ratio-lymph vessel invasion=3.0, P=0.04; hazard ratio-phosphohistone H3=6.9, P=0.002). Where age was <55 years, only phosphohistone H3 had independent prognostic value. Combinations of other features had no additional value. In conclusion, T1–2N0M0 invasive breast cancer patients ≥55 years with phosphohistone H3≥13, D2-40+/p63− defined lymph vessel invasion identifies a subgroup with a high risk of distant metastases." @default.
• W1993351741 created "2016-06-24" @default.
• W1993351741 creator A5003110329 @default.
• W1993351741 creator A5015030195 @default.
• W1993351741 creator A5039670147 @default.
• W1993351741 creator A5074952556 @default.
• W1993351741 creator A5082443222 @default.
• W1993351741 creator A5083578258 @default.
• W1993351741 date "2011-04-01" @default.
• W1993351741 modified "2023-10-15" @default.
• W1993351741 title "D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients" @default.
• W1993351741 cites W182059461 @default.
• W1993351741 cites W1961026612 @default.
• W1993351741 cites W1983182396 @default.
• W1993351741 cites W1983946189 @default.
• W1993351741 cites W1991575058 @default.
• W1993351741 cites W2002053831 @default.
• W1993351741 cites W2004602402 @default.
• W1993351741 cites W2010871781 @default.
• W1993351741 cites W2013595768 @default.
• W1993351741 cites W2013672003 @default.
• W1993351741 cites W2031259832 @default.
• W1993351741 cites W2035522305 @default.
• W1993351741 cites W2051453426 @default.
• W1993351741 cites W2058664008 @default.
• W1993351741 cites W2074095431 @default.
• W1993351741 cites W2100800745 @default.
• W1993351741 cites W2109444809 @default.
• W1993351741 cites W2115867454 @default.
• W1993351741 cites W2118413367 @default.
• W1993351741 cites W2128300772 @default.
• W1993351741 cites W2129296674 @default.
• W1993351741 cites W2143194298 @default.
• W1993351741 cites W2163814095 @default.
• W1993351741 cites W2166511179 @default.
• W1993351741 doi "https://doi.org/10.1038/modpathol.2010.199" @default.
• W1993351741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21317878" @default.
• W1993351741 hasPublicationYear "2011" @default.
• W1993351741 type Work @default.
• W1993351741 sameAs 1993351741 @default.
• W1993351741 citedByCount "16" @default.
• W1993351741 countsByYear W19933517412012 @default.
• W1993351741 countsByYear W19933517412014 @default.
• W1993351741 countsByYear W19933517412015 @default.
• W1993351741 countsByYear W19933517412016 @default.
• W1993351741 countsByYear W19933517412017 @default.
• W1993351741 countsByYear W19933517412018 @default.
• W1993351741 countsByYear W19933517412019 @default.
• W1993351741 countsByYear W19933517412020 @default.
• W1993351741 countsByYear W19933517412021 @default.
• W1993351741 countsByYear W19933517412022 @default.
• W1993351741 countsByYear W19933517412023 @default.
• W1993351741 crossrefType "journal-article" @default.
• W1993351741 hasAuthorship W1993351741A5003110329 @default.
• W1993351741 hasAuthorship W1993351741A5015030195 @default.
• W1993351741 hasAuthorship W1993351741A5039670147 @default.
• W1993351741 hasAuthorship W1993351741A5074952556 @default.
• W1993351741 hasAuthorship W1993351741A5082443222 @default.
• W1993351741 hasAuthorship W1993351741A5083578258 @default.
• W1993351741 hasBestOaLocation W19933517411 @default.
• W1993351741 hasConcept C121608353 @default.
• W1993351741 hasConcept C126322002 @default.
• W1993351741 hasConcept C142724271 @default.
• W1993351741 hasConcept C143998085 @default.
• W1993351741 hasConcept C144301174 @default.
• W1993351741 hasConcept C181152851 @default.
• W1993351741 hasConcept C2778740770 @default.
• W1993351741 hasConcept C2779013556 @default.
• W1993351741 hasConcept C2779720271 @default.
• W1993351741 hasConcept C2780849966 @default.
• W1993351741 hasConcept C2780965494 @default.
• W1993351741 hasConcept C38180746 @default.
• W1993351741 hasConcept C530470458 @default.
• W1993351741 hasConcept C71924100 @default.
• W1993351741 hasConceptScore W1993351741C121608353 @default.
• W1993351741 hasConceptScore W1993351741C126322002 @default.
• W1993351741 hasConceptScore W1993351741C142724271 @default.
• W1993351741 hasConceptScore W1993351741C143998085 @default.
• W1993351741 hasConceptScore W1993351741C144301174 @default.
• W1993351741 hasConceptScore W1993351741C181152851 @default.
• W1993351741 hasConceptScore W1993351741C2778740770 @default.
• W1993351741 hasConceptScore W1993351741C2779013556 @default.
• W1993351741 hasConceptScore W1993351741C2779720271 @default.
• W1993351741 hasConceptScore W1993351741C2780849966 @default.
• W1993351741 hasConceptScore W1993351741C2780965494 @default.
• W1993351741 hasConceptScore W1993351741C38180746 @default.
• W1993351741 hasConceptScore W1993351741C530470458 @default.
• W1993351741 hasConceptScore W1993351741C71924100 @default.
• W1993351741 hasIssue "4" @default.
• W1993351741 hasLocation W19933517411 @default.
• W1993351741 hasLocation W19933517412 @default.
• W1993351741 hasLocation W19933517413 @default.
• W1993351741 hasOpenAccess W1993351741 @default.
• W1993351741 hasPrimaryLocation W19933517411 @default.
• W1993351741 hasRelatedWork W1999904750 @default.
• W1993351741 hasRelatedWork W2033499417 @default.
• W1993351741 hasRelatedWork W2080383090 @default.
• W1993351741 hasRelatedWork W2333468506 @default.

• next